Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
492
datasets available to search
ShareScore release 0.9.0
Dataset results
492 results for “EGFR mutations;”
Non-interventional Study for Real-world Data of Afatinib Treatment in First-line Setting and of Subsequent Therapies for Patients With Advanced Epidermal Growth Factor Receptor (EGFR) Mutation-positiv
ClinicalTrials.gov study NCT04795245. IPD Sharing: NO. Countries: 1. Publications: 1.
TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
ClinicalTrials.gov study NCT04129502. IPD Sharing: YES. Countries: 24. Publications: 1.
Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 (Afatinib) Plus Sirolimus (Rapamune®) in Patients With Non-small Cell Lung Cancer Harbouring an EGFR Mutation and/or Disease Progression F
ClinicalTrials.gov study NCT00993499. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)
ClinicalTrials.gov study NCT03974022. IPD Sharing: NO. Countries: 13. Publications: 2.
Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC
ClinicalTrials.gov study NCT02474355. IPD Sharing: Not stated. Countries: 16. Publications: 3.
First-line Treatment for Adenocarcinoma Patients With Epidermal Growth Factor Receptor (EGFR) Mutation
ClinicalTrials.gov study NCT00344773. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations
ClinicalTrials.gov study NCT02954523. IPD Sharing: NO. Countries: 1. Publications: 1.
A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations
ClinicalTrials.gov study NCT01609543. IPD Sharing: Not stated. Countries: 3. Publications: 1.
Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR
ClinicalTrials.gov study NCT01854034. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study of Erlotinib (Tarceva) Versus Gemcitabine/Cisplatin as First-line Treatment in Patients With Non-small Cell Lung Cancer With EGFR Mutations
ClinicalTrials.gov study NCT01342965. IPD Sharing: Not stated. Countries: 3. Publications: 2.
Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutation
ClinicalTrials.gov study NCT03414814. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lun
ClinicalTrials.gov study NCT05388669. IPD Sharing: YES. Countries: 20. Publications: 1.
Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations
ClinicalTrials.gov study NCT00977470. IPD Sharing: NO. Countries: 1. Publications: 1.
Icotinib for Completed Resected IB NSCLC With EGFR Mutation
ClinicalTrials.gov study NCT02264210. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L
ClinicalTrials.gov study NCT02864251. IPD Sharing: Not stated. Countries: 10. Publications: 1.
A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progr
ClinicalTrials.gov study NCT04042558. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer
ClinicalTrials.gov study NCT04426825. IPD Sharing: YES. Countries: 1. Publications: 1.
Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)
ClinicalTrials.gov study NCT04248829. IPD Sharing: YES. Countries: 13. Publications: 2.
Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC
ClinicalTrials.gov study NCT01203917. IPD Sharing: Not stated. Countries: 13. Publications: 1.
GIOTRIF in First Line Therapy of Advanced NSCLC With EGFR-mutations
ClinicalTrials.gov study NCT02047903. IPD Sharing: Not stated. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.